Cel Sci (CVM) Change in Acquisitions & Divestments (2021 - 2022)

Cel Sci (CVM) posted Change in Acquisitions & Divestments of $5.4 million for Q3 2022, up 200.0% sequentially from -$5.4 million in Q1 2022.

Cel Sci (CVM) Change in Acquisitions & Divestments (2021 - 2022) Analysis & Trends

Cel Sci has reported Change in Acquisitions & Divestments for 2 years, with the latest figure at $5.4 million in Q3 2022.

Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $5.4 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $5.4 million (changed N/A YoY) and the FY2022 annual result came in at $6.2 million, changed N/A from the prior year.
Change in Acquisitions & Divestments improved to $5.4 million in Q3 2022 per CVM's latest filing, from -$5.4 million in the prior quarter.
Over five years, Change in Acquisitions & Divestments peaked at $6.2 million in Q4 2021 and troughed at -$5.4 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cel Sci	2.12 Mn	-4.42 Mn	-

Download Data